U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.47
    -0.03 (-0.05%)
     
  • Gold

    1,783.80
    +21.10 (+1.20%)
     
  • Silver

    22.45
    +0.17 (+0.76%)
     
  • EUR/USD

    1.1312
    +0.0006 (+0.0566%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.85
    +2.90 (+10.38%)
     
  • GBP/USD

    1.3237
    -0.0065 (-0.4885%)
     
  • USD/JPY

    112.7590
    -0.4500 (-0.3975%)
     
  • BTC-USD

    53,733.18
    -3,140.88 (-5.52%)
     
  • CMC Crypto 200

    1,364.70
    -77.06 (-5.34%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Recap: Epizyme Q3 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Epizyme (NASDAQ:EPZM) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 37.50% year over year to ($0.55), which beat the estimate of ($0.60).

Revenue of $3,566,000 decreased by 37.60% year over year, which missed the estimate of $5,430,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 06, 2020

View more earnings on EPZM

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/7y95p5e9

Recent Stock Performance

Company's 52-week high was at $27.82

52-week low: $11.03

Price action over last quarter: Up 3.99%

Company Profile

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.